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ABSTRACT
Objective: The objective of this study was to compare the effect of chitosan, lifestyle modification, and combination of chitosan and lifestyle 
modification on body mass index (BMI) in obese patients.
Methods: A prospective, randomized, open-label comparative study conducted for the period of 24 weeks. The study population was enrolled in three 
groups (chitosan 500 mg BD, lifestyle modification, and chitosan 500 mg BD and lifestyle modification). Data were analyzed using “t”-test and ANOVA.
Results: There is a reduction in BMI in all the three groups. However, when we combined chitosan and lifestyle modification, there is pronounced 
reduction in BMI, which is statistically significant (p<0.0001).
Conclusions: Chitosan and lifestyle modification have more pronounced effect on reduction on BMI as compared to monotherapy alone.
Keywords: Body mass index, Chitosan, Lifestyle modification.
INTRODUCTION
Obesity has become a major health problem worldwide, affecting people 
across all ages, sex, ethnicities, and races [1]. It is a medical condition 
in which excess body fat gets accumulated to the extent that it may 
have an adverse effect on health, leading to reduced life expectancy and 
increased morbidity and mortality due to cardiometabolic disorders. 
Obesity also has a serious impact on psychosocial and reproductive life 
of patients [2].
In 2013, an estimated 2.1 billion adults were overweight as compared 
to 857 million in 1980. Obesity has reached epidemic proportions 
in India in the 21st century, with morbid obesity affecting 5% of the 
country’s population. In Northern India, it was most prevalent in 
urban populations (male – 5.5% and female – 12.6%) followed by the 
urban slums (male – 1.9% and female – 7.2%). Obesity rates are low 
in rural populations (male – 1.6% and female – 3.8%) [3]. In old age, it 
is associated with increased morbidity and reduction in quality of life. 
The relative increase in mortality is less in old as compared to young 
adults and body weight associated with maximal survival increases 
with advancing age [4].
BMI is the most commonly used measure for monitoring the prevalence 
of overweight and obesity at the population level. It is also the most 
commonly used way of estimating whether an individual person 
is overweight or obese. People are considered obese when their 
BMI exceeds 30 kg/m2 [5]. In collaboration with the WHO Western 
Pacific Regional Office, the International Obesity Taskforce turned its 
attention to the Asian Pacific region in its publication. The Asia-Pacific 
Perspective: Redefining obesity and its treatment [6].
According to this, BMI is classified as follows:
•	 <18.5	kg/m2 – Underweight
•	 18.5–22.9	kg/m2 – Normal
•	 23.0–24.9	kg/m2 – At-risk for obesity
•	 25.0–29.9	kg/m2 – Obese I
•	 ≥30	kg/m2 – Obese II.
As a person’s body fat increases, both BMI and future risk of 
obesity-related illness also increase. BMI is an easy, cheap, and 
noninvasive method of assessing excess body fat [7].
Obesity leads to sedentary lifestyle and vice versa and this nexus leads 
to cascades of various diseases. Lifestyle modification and nutritional 
therapy are the mainstays of treatment. Diet quality can be improved 
by reducing the consumption of energy-dense foods such as those 
with high sugar, saturated fat and by increasing the intake of dietary 
fibers [8]. Although lifestyle modification and exercise are mainstays 
of the obesity treatment, still many patients are not able to achieve 
the desire goal of weight loss. There are several pharmacotherapies 
which are directed to treat obesity. These approaches include limiting 
the absorption of food, suppressing appetite, reducing food intake, and 
altering metabolism or increasing energy expenditure through action 
on central nervous system [9].
Antiobesity drugs such as sibutramine, rimonabant, orlistat, and 
topiramate are not recommended nowadays due to their non-safety and 
non-tolerability. Considering all this, in obesity management, one of the 
most efficient and safe methods could be reduction in fat intake, as it is 
directly associated with total fat consumption. A substance which acts 
by reducing the dietary absorption of fat is chitosan. Hence, chitosan 
can be used as an alternative to other antiobesity drugs.
Chitosan, glycosaminoglycans (GAGs), is colorless, odorless, and 
semi-crystalline flaky polymer which is obtained from the hard outer 
skeleton of shellfish, including crab, lobsters, and shrimp and by 
treating it with alkali sodium hydroxide. Chemically, it is composed 
of	 randomly	 distributed	 β-(1–4)	 linked	 D-glucosamine	 (deacetylated	
unit) and N-acetyl-D-glucosamine (acetylation unit). It is obtained by 
the deacetylation of chitin through a series of enzymatic and chemical 
treatments. It swells up giving the feeling of satiety by physically filling 
the stomach [10]. It contains high amino groups (pK 6.2–7.0) and it is 
water soluble but not soluble in high pH conditions [11]. By inhibiting 
pancreatic lipase activity, chitosan can reduce the absorption of dietary 
fat in the intestines. Besides, it can bind and precipitate fat in the 
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intestines so that it is not absorbed. The cationic chitosan binds with 
anionic carboxyl groups of fatty acids and bile acids, it also interferes 
with emulsification of neutral lipids such as cholesterol and other 
sterols by binding them with hydrophobic interaction; thus, fat and 
cholesterol absorption from the gastrointestinal tract are reduced [12].
Chitosan will be very effective if combine with lifestyle modification 
such as diet and exercise. It will give an effective result in reducing 
weight and ultimately reducing obesity and its associated complications. 
Introduction of chitosan along with lifestyle modification can avoid 
many risks associated with pharmacotherapy and surgical intervention 
in the form of bariatric surgery. A study done by Schiller et al. revealed 
decreased mean weight (1 kg) in the chitosan treatment group while it 
was found to be increased (1.5 kg) in the placebo group significantly. 
Furthermore, BMI was found to be significantly decreased in the 
treatment group [13]. In a study conducted by Pittler et al. on chitosan 
for weight reduction found no significant differences between groups in 
any outcome measures [14].
Many antiobesity drugs are available commercially, but there were 
no studies carried out in Aurangabad and adjoining rural areas using 
chitosan as an antiobesity drug. Considering the benefits of chitosan in 
control of obesity, we have decided to do this study on chitosan.
MATERIALS AND METHODS
A 24-week randomized comparative open-label single-center 
prospective clinical study was conducted in the outpatients of the 
Department of Medicine in collaboration with the Department of 
Pharmacology at Mahatma Gandhi Missions (MGMs) Medical College 
and Hospital, Aurangabad. It was conducted as per International 
Conference on Harmonization Good Clinical Practice guideline and 
after obtaining permission from the institutional ethics committee 
(MGM – ECRHS/2014/184). A total of 80 patients were screened, of 
which 60 patients were enrolled for the study after fulfilling the inclusion 
criteria. Patients were enrolled randomly by chit method in this study.
Inclusion criteria





















Patients were divided into three groups and each group comprised 
20 patients:
Group-I: Chitosan 500 mg BD
Group-II:	Lifestyle	modification
Group-III:	Chitosan	500	mg	BD	and	lifestyle	modification
•	 Lifestyle	modification:	Diet	chart by dietician, 30 min brisk walking 
daily, and salt-restricted diet
•	 Patients	were	assessed	at	baseline	and	at	24	weeks	for	the	following:	
Weight, height, and BMI.
The following formula is used for BMI calculation:
BMI = weight in kg/(height in m)2
Duration of the study was 6 months. Statistical analysis was done using 
paired “t”-test to measure the difference within the group and ANOVA 
to measure differences among the group.
Study flowchart
PATIENTS ARRIVAL 
SCREENING AS PER INCLUSION AND EXCLUSION CRITERIA 
FULFILLMENT                                                                      NON -FULFLLMENT    
EXCLUSION 
INCLUSION, INFORMED CONSENT 
SCREENING AT BASELINE 
Group I                                          Group II                                                Group III
(Chitosan 500 mg)       (Lifestyle modification)      (Chitosan 500 mg +Lifestyle modification) 
ASSESSMENT AT 24 WEEKS 
ANALYSIS, RESULT, CONCLUSION 
RESULTS
A total of 60 patients of both genders enrolled and evaluated. Patients 




Table 1 shows the age- and gender-wise distribution of the subjects 
under the study, chitosan group (Group I). About 35% were between 
the age group of 20 and 30 and 65% were from 31 to 40. Likewise, 60% 
were male and 40% were female.
Table 2 shows mean difference before and after treatment on BMI with 
chitosan as 1.67. By applying paired t-test, there is highly significant 
reduction in BMI (p=0.0001) in this group (n=20).
Table 3 shows the age- and gender-wise distribution of the subjects 
under the study, lifestyle modification (Group II). About 50% were 
between the age group of 20 and 29 and 50% were from 30 to 39. 
Likewise, 50% were male and 50% were female.
Table 4 shows mean difference before and after treatment with 
lifestyle modification on BMI as 0.95. By applying paired t-test, 
there is highly significant reduction in BMI (p=0.0001) in this group 
(n = 20).
Table 5 shows the age- and gender-wise distribution of the subjects 
under the study, chitosan and lifestyle modification (Group III). About 
40% were between the age group of 20 and 30 and 60% were from 31 
to 40. Likewise, 65% were male and 35% were female.
Table 6 shows mean difference before and after treatment with 
chitosan and lifestyle modification on BMI as 2.77. By applying paired 
t-test, there is highly significant reduction in BMI (p=0.0001) in this 
group (n = 20).
Table 7 shows percent reductions in each group. In Group I, percent 
reduction in BMI is 5.73. In Group II, percent reduction in BMI is 3.17. 
In Group III, percent reduction in BMI is 2.77.
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Table 8 shows that by applying ANOVA in Group I, II, and III, p=0.05 
which means that the differences in reducing BMI in all three groups 
were significant.
Baseline demographic characteristics (mean±standard deviation) for 
patients in the chitosan Group I were age 32.45 (±5.75) years; lifestyle 
modification Group II were age 29.00 (±6.15); and combination of 
chitosan and lifestyle modification Group III were age 32.00 (±1.09). 
There was no significant difference between the baseline demographics 
of study participants.
Effect on BMI in all groups
There was a reduction in the mean body weight over a period of 
6 months. In chitosan group (GroupI), body weight was reduced 
from 29.98 ± 2.79 at baseline to 28.31±2.80 which was statistically 
significant (P < 0.0001) when compared with baseline measurements. 
The percent reduction in BMI was 5.73%. In lifestyle modification 
group (Group II), body weight was reduced from 30.36 ± 3.20 at 
baseline to 29.41 ± 3.04 which was statistically significant (P < 
0.0001) when compared with baseline measurements. The percent 
reduction in BMI was 3.17%. In chitosan and lifestyle modification 
group (Group III), body weight was 32.67 ± 0.67 at baseline and 
29.90 ± 0.63 was at the end of the study which was statistically 
significant (P < 0.0001). The percent reduction in BMI was 2.77%.
DISCUSSION
Obesity is the most common metabolic disorder which results from 
excess accumulation of adipose tissue in the body. The prevalence of 
obesity is increasing throughout the world. It is associated with many 
comorbid conditions such as type II diabetes, cardiovascular diseases, 
hypertension, and hyperlipidemia and musculoskeletal diseases.
Obesity has reached epidemic proportions in India in the 21st century, 
with morbid obesity affecting 5% of the country’s population. 
Urbanization, modernization, and changing dietary pattern have been 
associated with increased prevalence of obesity. Obesity rates were the 
lowest in rural populations than the urban population. Socioeconomic 
status also had an effect on the growing epidemic of obesity. Obesity in 
old age is associated with increased morbidity, mortality, and reduction 
in quality of life due to musculoskeletal problems.
There are many methods for the assessment of obesity, but BMI is the 
most commonly used method to classify obesity. By this, we can come to 
know the people who are at high risk of developing the diseases which 
are mainly associated with obesity. BMI cutoff points for obesity have 
many uses, which are primarily applicable to Asian countries. They 
are used clinically to screen high-risk individuals for cardiac metabolic 
disorder, to identify individuals for absolute risk assessment, and to 
determine the type and intensity of treatment. Raised BMI also increases 
the risks of cancer of the breast, colon, prostate, endometrium, kidney, 
and gallbladder.
Lifestyle modification plays an important role in the treatment of 
obesity. It mainly consists of brisk walking for 30 min and a low-
calorie diet as gave the dietician. Physical activity plays a critical role in 
improving cardiovascular health in both the average weight and obese 
Table 5: Sociodemographic characteristics of the study 
population for chitosan therapy and lifestyle modification 
intervention (n=20)







Table 7: Percentage reduction in body mass index in all three 
groups
Group Mean difference 
(before and after treatment)
Percentage 
reduction in BMI (%)
Group I 1.67 5.73 ↓
Group II 0.95 3.17 ↓
Group III 8.85 2.77 ↓
BMI: Body mass index
Table 8: Comparison for all three groups by ANOVA
Comparison groups F p
Group I versus II versus III 3.763 0.05*
p>0.05	–	Not	significant,	*p<0.05	–	Significant,	***p<0.001	–	Highly	significant
Table 1: Sociodemographic characteristics of the study 
population for chitosan (n=20)







Table 2: Effect of chitosan on body mass index before and after 
treatment




Chitosan 29.9±2.79 28.31±2.80 1.67 12.32 0.0001
Table 3: Sociodemographic characteristics of the study 
population for lifestyle modification (n=20)







Table 4: Effect of lifestyle modification on body mass index 
before and after intervention






30.36±3.2 29.41±3.04 0.95 8.94 0.0001
Table 6: Effect of chitosan therapy and lifestyle modification 
intervention on body mass index before and after treatment







32.67±0.67 29.90±0.63 2.77 14.17 0.0001
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individuals. Increased physical activity helps to lower the accumulation 
of fats in the body. Low-calorie diet provides a calorie deficit of 
500–1000 kcal/day from maintenance requirement and is important 
for weight loss and prevention of weight regain. Low-fat diets provide 
25%–30% of calories from fat. They produce weight loss primarily by 
decreasing caloric intake. Very low-calorie diet of 200–800 kcal/day 
is often in the form of liquid nutritional supplement and results in the 
most rapid weight loss. It is appropriate only when the patient faces a 
major health risk and the physician has determined that such a diet can 
be used safely.
Chitosan is the drug which is used for the treatment of obesity. It is 
GAGs.	 Chemically,	 it	 is	 composed	 of	 randomly	 distributed	 β-(1–4)	
linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine 
(acetylation unit). It is obtained by the deacetylation of chitin through 
a series of enzymatic and chemical treatments. It swells up giving the 
feeling of satiety by physically filling the stomach. It inhibits pancreatic 
lipase activity and reduces the absorption of dietary fat in the intestines. 
It can bind and precipitate fat in the intestines so that it is not absorbed. 
It also helps for reduction in the absorption of fat and cholesterol. Thus, 
it helps in the reduction of weight.
Antiobesity drugs such as sibutramine, rimonabant, orlistat, and 
topiramate are not recommended nowadays due to their non-safety and 
non-tolerability. In the present study, we found that administration of 
chitosan for 24 weeks, in all three groups decreases BMI. The difference 
was statistically highly significant (p=0.0001). When we had use chitosan 
as monotherapy, these results were comparable to the study conducted 
by Schiller et al., [13] which revealed that decreased mean weight in the 
treatment group and also BMI were found to be significantly decreased in 
the absence of other lifestyle modifications. Furthermore, combination 
therapy of chitosan and lifestyle intervention for 24 weeks, there was 
a decrease in BMI and the difference was statistically highly significant 
(p=0.0001). This result was correlated with the study conducted by 
Giustina and Ventura [15] with chitosan and low-caloric diet, which 
revealed that greater reduction in mean body weight and BMI, which 
were statistically significant. When we have compared all the groups 
in this study, we found that the results were statistically significant 
after 24 weeks of therapy, but combined effect was more significant as 
compared to monotherapy. There were no adverse events during the 
study. No dropout was observed, which states that overall, the study 
treatment was safe and well tolerated by all study subjects.
Limitation of the study is small sample size and it is a single-center 
study.
CONCLUSIONS
In the present study, chitosan and lifestyle modification intervention 
as monotherapy and in combination reduce BMI significantly after 
24 weeks of treatment. The advantage of using combination therapy 
seen in Group III as it has reduced BMI to a greater extent. The result 
of our study reveals that a combination of chitosan and lifestyle 
modification produced a more pronounced effect on BMI as compared 
to monotherapy. In our study, we found that chitosan, lifestyle 
modification, and combination of both have effect on reduction of BMI. 
This can be helpful for the treatment of obesity, which will help to 
reduce high risk of developing diseases associated with obesity. From 
this study, we conclude that chitosan and lifestyle modification alone 
have a significant reduction in BMI, but more pronounced effect has 
seen with the combination of chitosan and lifestyle modification.
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